Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities
Net income	$ 5,581.7	$ 6,193.7	$ 8,318.4
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Gain related to disposition of Elanco (Note 19)	0.0	0.0	(3,680.5)
Gain on sale of antibiotic business in China (Note 3)	0.0	0.0	(309.8)
Depreciation and amortization	1,547.6	1,323.9	1,232.6
Debt extinguishment loss (Note 11)	405.2	0.0	252.5
Change in deferred income taxes	(802.3)	(134.5)	62.4
Stock-based compensation expense	342.8	308.1	312.4
Net investment gains	(178.0)	(1,438.5)	(403.1)
Acquired in-process research and development (Note 3)	874.9	660.4	239.6
Other non-cash operating activities, net	511.4	333.9	499.3
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables—(increase) decrease	(1,278.3)	(1,350.2)	(127.2)
Inventories—(increase) decrease	(235.9)	(533.4)	(258.7)
Other assets—(increase) decrease	1,515.4	(457.1)	(602.3)
Income taxes payable—increase (decrease)	(359.7)	322.0	(221.3)
Accounts payable and other liabilities—increase (decrease)	(664.1)	1,271.3	(477.7)
Net Cash Provided by Operating Activities	7,260.7	6,499.6	4,836.6
Cash Flows from Investing Activities
Purchases of property and equipment	(1,309.8)	(1,387.9)	(1,033.9)
Proceeds from sales and maturities of short-term investments	47.4	129.7	136.6
Purchases of short-term investments	(83.5)	(11.4)	(42.7)
Proceeds from sales of noncurrent investments	800.0	757.1	609.8
Purchases of noncurrent investments	(929.9)	(358.7)	(247.5)
Purchases of in-process research and development	(563.4)	(641.2)	(319.6)
Cash paid for acquisitions, net of cash acquired (Note 3)	(747.4)	(849.3)	(6,917.7)
Cash distributed to Elanco upon disposition	0.0	0.0	(374.0)
Cash received for sale of antibiotic business in China	0.0	0.0	354.8
Other investing activities, net	24.3	102.8	(248.7)
Net Cash Used for Investing Activities	(2,762.3)	(2,258.9)	(8,082.9)
Cash Flows from Financing Activities
Dividends paid	(3,086.8)	(2,687.1)	(2,409.8)
Net change in short-term borrowings	(4.0)	(1,494.2)	995.4
Proceeds from issuance of long-term debt	2,410.8	2,062.3	6,556.4
Repayments of long-term debt	(1,905.4)	(276.5)	(2,866.4)
Purchases of common stock	(1,250.0)	(500.0)	(4,400.0)
Other financing activities, net	(295.9)	(241.6)	(200.1)
Net Cash Used for Financing Activities	(4,131.3)	(3,137.1)	(2,324.5)
Effect of exchange rate changes on cash and cash equivalents	(205.7)	216.0	(89.9)
Net increase (decrease) in cash and cash equivalents	161.4	1,319.6	(5,660.7)
Cash and cash equivalents at beginning of year (2019 includes $677.5 of discontinued operations)	3,657.1	2,337.5	7,998.2
Cash and Cash Equivalents at End of Year	$ 3,818.5	$ 3,657.1	$ 2,337.5